Table 2.
Serial no. | Tumor biological criteria that may disturb 3BP effects | Suggested practical solutions | Rationale |
---|---|---|---|
1 | Leaky nature of the tumor-associated blood vessels | Coating 3BP in liposomes, PEGylated liposomes, perillyl alcohol or other formulations | To increase the molecular size and prevent 3BP leakage outside the tumor tissues |
2 | Large-sized gaps between the endothelial cells lining the tumor capillaries (100–780 nm) depending on the cancer type | Coating 3BP in liposomes, PEGylated liposomes, perillyl alcohol or other formulations | To increase the molecular size and prevent 3BP leakage outside the tumor tissues vs normal endothelium (5–10 nm)24 |
3 | Lacking adequate lymphatic drainage (in solid tumors) | Formulating 3BP in liposomes | To enhance 3BP trapping inside the tumors |
4 | Enhanced tumor permeability to chemotherapeutics (EPR effect causing 3BP efflux and wash out) | Formulating 3BP in liposomes, PEG or perillyl alcohol | To enhance 3BP trapping inside the tumors |
5 | Short retention time of low-molecular-weight drugs (eg, 3BP)25,26 | Formulating 3BP in liposomes, PEG or perillyl alcohol | To enhance 3BP trapping inside the tumors |
6 | No accumulation of very small liposomes in the tumors | Formulating 3BP in liposomes (>200 nm), PEG or perillyl alcohol | To increase the molecular size of 3BP formulations and prevent 3BP leakage outside the tumor tissues |
7 | Extravasation of very small liposomes outside the tumors27 | Formulating 3BP in liposomes, PEG or perillyl alcohol (>200 nm) | To increase the molecular size of 3BP formulations and prevent 3BP leakage outside the tumor tissues |
8 | Extensive angiogenesis | Formulating 3BP in liposomes coated with anti-VEGF monoclonal antibodies, PEG or perillyl alcohol | To facilitate 3BP-induced antiangiogenesis |
9 | Increased expression of mediators of cell surface permeability (may increase leakiness) | Formulating 3BP in liposomes, PEG or perillyl alcohol | Formulating 3BP in liposomes having tagged suitable ligands to facilitate tumor targeting and 3BP retention |
10 | Acidic tumor pH (neutralizes alkaline chemotherapeutics, eg, 3BP dissolved in alkaline medium) | Avoid dissolving 3BP in alkaline solutions | To preserve 3BP chemistry and prevent chemical neutralization of 3BP |
11 | High tumor GSH | Formulating 3BP in liposomes, PEG or perillyl alcohol | To mask 3BP from thiol groups in GSH and proteins |
12 | Attachment of crude 3BP to serum and tissue proteins | Formulating 3BP in liposomes, PEG or perillyl alcohol | To mask 3BP from thiol groups in serum and tissue proteins |
13 | Lack of effective tumor targeting | Formulating 3BP in liposomes, PEG or perillyl alcohol | To allow better 3BP retention inside the tumor tissues based on biological differences that distinguish the tumors from normal tissues |
Abbreviations: 3BP, 3-Bromopyruvate; EPR, enhanced permeability and retention; GSH, glutathione; PEG, polyethylene glycol; VEGF, vascular endothelial growth factor.